CAMBRIDGE, Mass.--(BUSINESS WIRE)--Editas Medicine, a leading genome editing company, today announced the appointment of Andrew Hack, M.D., Ph.D., as chief financial officer. Dr. Hack brings to Editas a deep understanding of capital markets, strong relationships across the financial community and more than a decade of experience analyzing the successes and failures of biopharmaceutical companies.
"Genome editing is the next great frontier in medicine"
"Andrew thinks strategically about how to build biotech companies, and he brings substantial expertise in corporate finance to the Editas team," said Katrine Bosley, CEO, Editas Medicine. "His depth of experience and leadership will be invaluable as we continue to build Editas Medicine into a leading genome editing company. We are very pleased to welcome him to the team."
"Genome editing is the next great frontier in medicine," said Dr. Hack. "I am excited to join Editas, a pioneering genomic medicine company with such a strong financial and scientific foundation, as we start to advance the development of its CRISPR/Cas9 technology into therapeutics that will have a far-reaching impact for a wide range of genetically-driven diseases."
Dr. Hack joins Editas from Millennium Management, where, as portfolio manager, he ran a healthcare fund focused on biotechnology, pharmaceutical, and medical device companies. Before joining Millennium, Dr. Hack was a healthcare analyst at HealthCor Management, Carlyle-Blue Wave Partners and the MPM BioEquities Fund. While at Carlyle-Blue Wave, Dr. Hack was named one of the Rising Stars of Hedge Funds by Institutional Investor. He started his investment career covering the biotechnology sector at Bank of America. Before going to work on Wall Street, Dr. Hack co-founded Reify Corporation, a life science tools and drug discovery company.
Dr. Hack received his B.A. in biology with special honors from the University of Chicago, where he also received his M.D. and Ph.D., was named the inaugural Frank Family Scholar and received awards from the American Heart Association and the American Society for Cell Biology.
About Editas Medicine
Editas Medicine is a leading genome editing company and part of a transformational new area of health care – genomic medicine. The company was founded by pioneers and world leaders in genome editing bringing specific expertise in CRISPR/Cas9 and TALENs technologies. The company's mission is to translate its proprietary technology into novel solutions to treat a broad range of genetically driven diseases. For more information, visit www.editasmedicine.com.
Pure Communications, Inc.
Dan Budwick, 973-271-6085